Segment Information (Tables)

9 Months Ended

Oct. 02, 2020

Segment Reconciliation [Abstract]

Reconciliation of Revenue from Segments to Consolidated

The following table presents sales from continuing operations by product line (in thousands).

	Three Months Ended				Nine Months Ended
	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019
Segment sales from continuing operations by product line:
Medical
Cardio & Vascular	$	124,596	$	148,581	$	432,885	$	451,552
Cardiac & Neuromodulation	72,909		106,533		252,404		337,932
Advanced Surgical, Orthopedics & Portable Medical	30,179		34,310		92,041		98,544
Total Medical	227,684		289,424		777,330		888,028
Non-Medical	8,258		14,163		27,153		44,429
Total sales from continuing operations	$	235,942	$	303,587	$	804,483	$	932,457

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The following table presents income from continuing operations for the Company’s reportable segments (in thousands).

	Three Months Ended				Nine Months Ended
	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019
Segment income from continuing operations:
Medical	$	28,777	$	62,648	$	120,903	$	182,734
Non-Medical	1,214		3,318		4,894		12,927
Total segment income	29,991		65,966		125,797		195,661
Unallocated operating income (expenses)(a)	9,767		(19,485)		(32,778)		(60,674)
Operating income	39,758		46,481		93,019		134,987
Unallocated expenses, net	(8,358)		(10,982)		(24,815)		(39,524)
Income from continuing operations before taxes	$	31,400	$	35,499	$	68,204	$	95,463

__________

(a) Unallocated operating income (expenses) for the three and nine months ended October 2, 2020 includes a net gain of $28.2 million related to a patent litigation judgment. Refer to Note 10 “Commitments and Contingencies” for additional information on this matter.